ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Co-stimulation"

  • 2022 American Transplant Congress

    Renal Function at Five Years from a Randomized Multicenter Trial of Belatacept-Based CNI Free and Early Steroid Withdrawal Immunosuppression

    E. Yanqui1, H. Hames1, A. R. Shields1, T. Shi1, A. L. Christianson1, J. Kremer2, A. Govil1, R. R. Alloway1, E. S. Woodle1

    1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH

    *Purpose: BENEFIT and BENEFIT EXT trials have demonstrated that belatacept-based immunosuppression was associated with improved long term renal allograft function compared to cyclosporine-based immunosuppression. Similar…
  • 2022 American Transplant Congress

    Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients

    A. Rizvi1, M. Kueht2, S. Hussain3, J. Fair2, R. Ramirez4, A. Gamilla-Crudo5, M. Mujtaba5

    1Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, 2Surgery, University of Texas Medical Branch, Galveston, TX, 3University of Texas Medical Branch, Houston, TX, 4Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, 5University of Texas Medical Branch, Galveston, TX

    *Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
  • 2022 American Transplant Congress

    Tolerant B Cells Suppress Memory B Cells in a Donor Specific Manner in CoB Mediated Transplantation Tolerance

    S. Durgam1, D. Yin1, M. Alegre2, A. Chong1

    1Surgery, section of transplant immunology, University of Chicago, Chicago, IL, 2Medicine, section of rheumatology, University of Chicago, Chicago, IL

    *Purpose: We previously reported that B cells in recipients made tolerant to fully mismatched heart allografts by anti-CD154+donor spleen cells (CoB) become dysfunctional in their…
  • 2022 American Transplant Congress

    Donor-Specificb Cell Dysfunction and Suppressive Ability Are Differentially Induced in Cob-Mediated Transplantation Tolerance

    S. Durgam1, D. Yin1, M. Alegre2, A. Chong1

    1Surgery, section of transplant immunology, University of Chicago, Chicago, IL, 2Medicine, section of rheumatology, University of Chicago, Chicago, IL

    *Purpose: B cells in mice tolerized to fully mismatched heart allografts with anti-CD154+donor spleen cells (CoB) are intrinsically dysfunctional and unable to differentiate into germinal…
  • 2022 American Transplant Congress

    Belatacept Augments Mixed Chimerism in a Novel Nonhuman Primate Kidney Transplant Tolerance Induction Protocol

    S. C. Kim, C. J. Little, J. H. Fechner, P. J. Chlebeck, J. Post, A. D'Alessandro, D. B. Kaufman

    University of Wisconsin, Madison, WI

    *Purpose: A novel protocol of antilymphocyte globulin (ATG), tomotherapy-based total lymphoid irradiation (TomoTLI), and adoptive cellular transfer was developed in a preclinical model of MHC-mismatched…
  • 2022 American Transplant Congress

    Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens

    H. Hames1, A. R. Shields1, E. Yanqui1, A. Christianson1, J. Kremer2, A. Govil1, E. S. Woodle1, R. R. Alloway1

    1University of Cincinnati, Cincinnati, OH, 2Christ Hospital, Cincinnati, OH

    *Purpose: A prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based, calcineurin inhibitor-free (CNI), early corticosteroid withdrawal (ESW) regimens with a tacrolimus (TAC)-based ESW…
  • 2022 American Transplant Congress

    Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)

    G. Divard1, O. Aubert1, M. Raynaud1, F. Vincenti2, L. Rostaing3, A. Durbach4, C. Legendre1, R. Vadanici5, A. Loupy1, -. BENEFIT & BENEFIT-EXT Investigators6

    1Paris Transplant Group, INSERM, Paris, France, 2UCSF, San Francisco, CA, 3Grenoble, Grenoble, France, 4APHP, Paris, France, 5BMS, Rueil Malmaison, France, 6BMS, New York, NY

    *Purpose: The iBox is a prognostication system for long-term kidney allograft survival, developed with mostly patients under a CNI based immunosuppression. Patients treated with a…
  • 2022 American Transplant Congress

    Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study

    G. Divard, C. Debiais, C. Legendre, O. Aubert, C. Lefaucheur, A. Loupy

    Paris Transplant Group, INSERM, Paris, France

    *Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…
  • 2022 American Transplant Congress

    CD8+ T Cells Differentiate into a CD43-expressing Effector Population After Transplantation

    G. Cohen, M. A. Kallarakal, S. M. Krummey

    Department of Pathology, Johns Hopkins University, Baltimore, MD

    *Purpose: Despite a significantly reduced toxicity profile and improved long-term graft function versus calcineurin inhibitors, widespread adaptation of belatacept (CTLA-4 Ig) has been limited due…
  • 2022 American Transplant Congress

    Conversion to Belatacept for Calcineurin Inhibitor Toxicities

    S. S. Patel, P. Jadav, M. Sekulic, S. Kudose, I. Batal, S. Mohan, R. Crew

    Columbia University Medical Center, New York, NY

    *Purpose: Calcineurin inhibitors (CNIs) have improved renal transplant (RTx) outcomes but are associated with significant toxicities. Belatacept provides better long-term outcomes than cyclosporine, has less…
  • 1
  • 2
  • 3
  • …
  • 30
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences